Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 6:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–136 of 136 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Hepatitis A Vaccine Clear all

Conditions: Hepatitis C
Interventions: AdCh3NSmut1, MVA-NSmut, Placebo; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 548 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2018
U.S. locations: 5
States / cities: San Francisco, California • Baltimore, Maryland • Albuquerque, New Mexico

Conditions: Hepatitis B
Interventions: HEPLISAV; Biological
Lead sponsor: Dynavax Technologies Corporation; Industry
Eligibility: 11 Years to 55 Years
Enrollment: 207 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 7
States / cities: Boardman, Ohio • Grove City, Pennsylvania • Pittsburgh, Pennsylvania + 3 more

Conditions: HIV Infections
Interventions: Hepatitis B virus vaccine with GM-CSF adjuvant, Hepatitis B virus vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2008
U.S. locations: 11
States / cities: Chicago, Illinois • St Louis, Missouri • New York, New York + 6 more

Conditions: Infant, Premature
Interventions: Vitamin A supplementation; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 1 Day to 3 Days
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Inflammation
Interventions: Influenza Virus Vaccine; Biological
Lead sponsor: Tulane University; Other
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2015
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Hepatitis A
Interventions: hepatitis A vaccine; Biological
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 6 Months to 25 Years
Enrollment: 248 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1996 – 2001
U.S. locations: 2
States / cities: Anchorage, Alaska

Conditions: Chronic Hepatitis B
Interventions: Selgantolimod, Placebo, Hepatitis B virus (HBV) OAV Therapy; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Neisseria Meningitidis, Haemophilus Influenzae Type b
Interventions: Hib-MenCY-TT (MenHibrix®), Pediarix®, Rotarix®, Prevnar 13®, PedvaxHIB®, Havrix®; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Weeks to 12 Weeks
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 26
States / cities: Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 23 more

Conditions: Overdose
Interventions: MI-CHANCE (TS + FTIR + MI), TS + FTIR + Flu and Hepatitis A Education; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 588 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: San Diego, California

Conditions: Hepatitis B, Hepatitis C, HIV, HIV Infections
Interventions: NCMIT, SCMIT; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 39 Years · Male only
Enrollment: 451 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Rubella, Measles, Mumps
Interventions: Priorix, M-M-R II, Varivax, Havrix, Prevnar 13; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Months to 15 Months
Enrollment: 5,016 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 62
States / cities: Dothan, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 56 more

Conditions: Healthy Volunteers
Interventions: hepatitis B vaccine; Biological
Lead sponsor: Emergent BioSolutions; Industry
Eligibility: 20 Years to 55 Years
Enrollment: 141 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Altamonte Springs, Florida • Frederick, Maryland

Conditions: Vaccine Exposure During Pregnancy
Interventions: Data collection; Other
Lead sponsor: VBI Vaccines Inc.; Industry
Eligibility: Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2032
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Lymphoma
Interventions: AREXVY, ABRYSVO, PREVNAR 20, PNEUMOVAX 23, Heplisav -B, PREVNAR 13, Shingrix; Drug · Biological
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 90 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2036
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infection, Hepatitis B
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 12 Years to 25 Years
Enrollment: 337 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 4
States / cities: Los Angeles, California • San Franciso, California • Washington D.C., District of Columbia + 1 more

Conditions: Hepatitis B
Interventions: Engerix™-B vaccine; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 20 Years and older
Enrollment: 667 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 10
States / cities: Huntsville, Alabama • Stockbridge, Georgia • Boise, Idaho + 7 more

Search by objective public record fields.

Staged Phase I/II Hepatitis C Prophylactic Vaccine

Open-Label Study of the Safety and Immunogenicity of HEPLISAV™ Hepatitis B Virus Vaccine

Safety and Effectiveness of an Adjuvant in Improving Immune Response to Hepatitis B Virus Vaccine in HIV Infected Individuals

Vitamin A Supplementation in Preterm Infants

Vaccine Efficacy in Diabetic and Elderly Patients

Immunogenicity Study of an Inactivated Hepatitis A Vaccine in Infants and Young Children

Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis B

Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age

Motivational Interviewing to Increase Uptake of Drug Checking and Safe Drug Use Behaviors to Reduce Overdose

Hepatitis B Virus (HBV) Prevention for Homeless at Risk for HBV/Hepatitis C Virus (HCV)/HIV

Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age

Hepatitis B Virus Antibody Booster Program for the Production of Hepatitis B Immune Globulin (HBIG)

PREHEVBRIO Pregnancy Outcomes Registry

Vaccine Responses in Patients With B Cell Malignancies

Hepatitis B Vaccine Genetics: A Substudy of ATN 024 and ATN 025

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus